{"title":"脑外伤史不会影响两个早期帕金森病队列中临床或病理结果的进展率。","authors":"Angus McNamara, Irina Baetu, Lyndsey Collins-Praino","doi":"10.1111/ene.70090","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>A history of traumatic brain injury (TBI) is associated with an increased risk of developing neurodegenerative disorders, including Parkinson's Disease (PD). However, TBI's influences on disease progression remain underassessed. This study explored whether a history of TBI influences the progression of pathological and clinical outcomes up to 5 years of follow-up in individuals with early PD.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Longitudinal data were extracted from the Parkinson's Progression Markers Initiative (PPMI) and the PostCEPT observational study. Participants in PostCEPT had complete head injury data, while PPMI participants were eligible if they completed the head injury section of the PD Risk Factor Questionnaire (<i>n</i> = 208). Principal component analysis was used to derive composite scores of cognitive ability and mood dysfunction, with motor outcomes calculated using the Movement Disorders Society Unified Parkinson's Disease Rating Scale. Progression of clinical and pathological outcomes up to 5 years and 4 years following study entry were compared, including subset analyses in PPMI examining injury severity.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Individuals with a history of TBI in the PPMI dataset exhibited a younger age of onset; however, a history of TBI did not affect progression rates of any assessed variables across both cohorts. Exploratory analysis determined that injury severity significantly predicted striatal dopamine transporter binding but accounted for only a small portion of outcome variance.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>While the history of TBI was associated with earlier PD onset, it did not correspond to a differential disease course. However, given differences in TBI characterisation between cohorts, additional research must be conducted to validate these findings.</p>\n </section>\n </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"32 3","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926254/pdf/","citationCount":"0","resultStr":"{\"title\":\"History of Traumatic Brain Injury Does Not Influence Rate of Progression of Clinical or Pathological Outcomes in Two Early Parkinson's Disease Cohorts\",\"authors\":\"Angus McNamara, Irina Baetu, Lyndsey Collins-Praino\",\"doi\":\"10.1111/ene.70090\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>A history of traumatic brain injury (TBI) is associated with an increased risk of developing neurodegenerative disorders, including Parkinson's Disease (PD). However, TBI's influences on disease progression remain underassessed. This study explored whether a history of TBI influences the progression of pathological and clinical outcomes up to 5 years of follow-up in individuals with early PD.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Longitudinal data were extracted from the Parkinson's Progression Markers Initiative (PPMI) and the PostCEPT observational study. Participants in PostCEPT had complete head injury data, while PPMI participants were eligible if they completed the head injury section of the PD Risk Factor Questionnaire (<i>n</i> = 208). Principal component analysis was used to derive composite scores of cognitive ability and mood dysfunction, with motor outcomes calculated using the Movement Disorders Society Unified Parkinson's Disease Rating Scale. Progression of clinical and pathological outcomes up to 5 years and 4 years following study entry were compared, including subset analyses in PPMI examining injury severity.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Individuals with a history of TBI in the PPMI dataset exhibited a younger age of onset; however, a history of TBI did not affect progression rates of any assessed variables across both cohorts. Exploratory analysis determined that injury severity significantly predicted striatal dopamine transporter binding but accounted for only a small portion of outcome variance.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>While the history of TBI was associated with earlier PD onset, it did not correspond to a differential disease course. However, given differences in TBI characterisation between cohorts, additional research must be conducted to validate these findings.</p>\\n </section>\\n </div>\",\"PeriodicalId\":11954,\"journal\":{\"name\":\"European Journal of Neurology\",\"volume\":\"32 3\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926254/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ene.70090\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ene.70090","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
History of Traumatic Brain Injury Does Not Influence Rate of Progression of Clinical or Pathological Outcomes in Two Early Parkinson's Disease Cohorts
Background
A history of traumatic brain injury (TBI) is associated with an increased risk of developing neurodegenerative disorders, including Parkinson's Disease (PD). However, TBI's influences on disease progression remain underassessed. This study explored whether a history of TBI influences the progression of pathological and clinical outcomes up to 5 years of follow-up in individuals with early PD.
Methods
Longitudinal data were extracted from the Parkinson's Progression Markers Initiative (PPMI) and the PostCEPT observational study. Participants in PostCEPT had complete head injury data, while PPMI participants were eligible if they completed the head injury section of the PD Risk Factor Questionnaire (n = 208). Principal component analysis was used to derive composite scores of cognitive ability and mood dysfunction, with motor outcomes calculated using the Movement Disorders Society Unified Parkinson's Disease Rating Scale. Progression of clinical and pathological outcomes up to 5 years and 4 years following study entry were compared, including subset analyses in PPMI examining injury severity.
Results
Individuals with a history of TBI in the PPMI dataset exhibited a younger age of onset; however, a history of TBI did not affect progression rates of any assessed variables across both cohorts. Exploratory analysis determined that injury severity significantly predicted striatal dopamine transporter binding but accounted for only a small portion of outcome variance.
Conclusion
While the history of TBI was associated with earlier PD onset, it did not correspond to a differential disease course. However, given differences in TBI characterisation between cohorts, additional research must be conducted to validate these findings.
期刊介绍:
The European Journal of Neurology is the official journal of the European Academy of Neurology and covers all areas of clinical and basic research in neurology, including pre-clinical research of immediate translational value for new potential treatments. Emphasis is placed on major diseases of large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases).